MI-SECOND-NATURE-BRANDS
26.4.2022 14:34:41 CEST | Business Wire | Press release
Funds managed by CapVest Partners LLP (“CapVest”), a leading international private equity investor, have closed the acquisition of Second Nature Brands (“the Company”), a Michigan-based creator of premium, nutritional and better for you snacks and treats, including Kar’s Nuts, Second Nature Snacks, and Sanders Chocolates, from a private equity fund affiliated with Palladium Equity Partners, LLC.
With a heritage stretching over 140 years, the Company is a leader in the fast-growing snacks and treats market, focussing on the nutritional and lifestyle needs of health-conscious consumers. The Company’s brands comprise Kar’s Nuts, the #1 branded trail mix delivering better-for-you, on-the-go fuelling snacks, Second Nature Snacks, a pioneer in natural, non-GMO-verified premium snacks and trail mixes created for a healthy, on-the-go lifestyle, and Sanders Chocolates, the leader in premium, small-batch, kettle-cooked sea salt caramels.
Commenting on the transaction, Othmane Khelladi, Partner, CapVest, said: “Second Nature Brands is a very exciting platform with ambitious plans to grow its presence in the highly attractive snacking and treats market. Through our ownership, we look forward to supporting Vic Mehren and his world-class team in accelerating growth through further investment in product innovation, category leadership and by scaling the existing platform through transformational acquisitions.”
Commenting on behalf of Second Nature Brands, CEO Vic Mehren said: “Our partnership with Palladium has been extraordinarily successful and we thank them for their contributions to Second Nature Brands. With their support, and through the efforts of our great Second Nature Brands team members, Second Nature Brands has transformed into a leader within Snacks and Treats. We’re now thrilled to be partnering with CapVest for our next phase of growth. The CapVest team’s deep consumer food experience will be invaluable as we work to build on our Snacks and Treats platform organically, and inorganically with strategic acquisitions.”CapVest has been investing in food businesses around the world for more over 20 years and has a deep understanding of the consumer food sector. Recent successes include the transformation of Valeo Foods from an Irish-only business with less than €200 million in sales, to a leading global ambient food group with over €1.1 billion in net sales operating in over 106 markets around the world.
CapVest was advised by William Blair (M&A) and Willkie Farr & Gallagher (Legal).
About CapVest
CapVest is a leading international private equity investor that partners with ambitious companies supplying essential goods and services to transform their businesses. As an active and patient investor, CapVest has established a strong record of success in delivering attractive returns by working closely with management in transforming the size and scale of its portfolio companies through a combination of organic and acquisition led growth. For more information, visit www.capvest.co.uk
About Second Nature Brands
Second Nature Brands is a leading creator of snacks and treats that make lives better, naturally. By investing in new product development, thoughtful ingredient sourcing, and innovative business processes, Second Nature Brands is reimagining premium and better-for-you snacks and treats. Under its growing family of brands, Kar’s Nuts®, Second Nature Snacks®, and Sanders Chocolates®, Second Nature Brands has an extensive distribution network across the United States and a growing direct-to-consumer eCommerce presence. Currently, Kar’s Nuts® and Second Nature Snacks® are two of the best-selling trail mix brands in the nation, including the #1 selling Kar’s Sweet ‘n Salty
Mix. Sanders Chocolates is one of the largest kettle-cooked, small-batch crafters of sea salt caramel treats in the U.S. Find out more at Second Nature Brands (www.secondnaturebrandsus.com ), Kar’s Nuts (www.karsnuts.com ), Second Nature Snacks (www.secondnaturesnacks.com ), and Sanders Chocolates (www.sanderscandy.com )
View source version on businesswire.com: https://www.businesswire.com/news/home/20220426005746/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Curatis: Double-Digit Revenue Growth in 2025 and Major Milestones for Corticorelin Achieved24.3.2026 07:00:00 CET | Press release
Curatis Holding AG (SIX:CURN, “Curatis”) reports business revenues of CHF 10.8m (+57%) for 2025. Curatis AG increased sales in its distribution business organically by 13%, from CHF 9.5m to CHF 10.8m. The net result improved from a loss of CHF 4.3m in 2024 to a loss of CHF 1.4m in 2025. Further key statements In September 2025, our development plan for corticorelin was validated at a meeting with the FDA, enabling Curatis to proceed toward a regulatory submission supporting a pivotal study in patients suffering from peritumoral brain edema (PTBE). In November 2025, Curatis raised CHF 1.2m to progress corticorelin. The cash position as of year end 2025 was comfortable, standing at CHF 1.9m. Recently, Curatis announced a license agreement for corticorelin for Japan with significant milestone payments. Business development and finances In 2025, product sales amounted to CHF 10.3m, while service revenue amounted to CHF 0.5m. On a full year basis, Curatis AG increased revenues in its distri
AAD 2026: Galderma Showcases Latest Evidence Supporting Its Full-Spectrum, Science-Driven Solutions for Diverse Skin Needs24.3.2026 07:00:00 CET | Press release
From its Therapeutic Dermatology portfolio, Galderma will present data on the efficacy and safety of Nemluvio® (nemolizumab) in different patient populations with moderate-to-severe atopic dermatitis, including late-breaking data in pediatric patients, and share four posters on AKLIEF® (trifarotene)1-8 Additional presentations related to Dermatological Skincare will explore how artificial intelligence can identify high-risk factors for sensitive skin and Cetaphil® in different skin types9 Data from Galderma’s Injectable Aesthetics portfolio will also show how its hyaluronic acid injectables, Restylane®, and neuromodulator, RelabotulinumtoxinA*, may address aesthetic needs across the face and décolletage10-14 A total of 22 presentations will reinforce the value of Galderma’s broad and comprehensive portfolio in meeting varied patient needs across Therapeutic Dermatology, Injectable Aesthetics and Dermatological Skincare Galderma (SIX: GALD), the pure-play dermatology category leader, wi
Avanzanite Expands French Operations and Appoints Constance Sabbagh as General Manager24.3.2026 07:00:00 CET | Press release
Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today announced its expansion into France, Europe’s second largest economy, and the appointment of Constance Sabbagh as General Manager, France. Following a €32 million Series A investment by MVM Partners announced in November 2025, Avanzanite is scaling its European infrastructure into a single, integrated platform across 32 countries – designed to bring rare disease medicines to patients in every European market. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260323639110/en/ Constance Sabbagh, General Manager, France “France is essential to Avanzanite’s European vision,” said Adam Plich, Co-founder and CEO of Avanzanite. “With its leadership in rare disease policy through its National Rare Disease Plans, care networks and scientific innovation, France is one of the most significant healthcare
HJS Foundation Releases JEP Protocol & HJS Framework: The "Black Box" for AI, Enabling Verifiable Human Oversight24.3.2026 04:36:00 CET | Press release
HJS Foundation (Human Judgment Systems Foundation) today released two complementary solutions: the Judgment Event Protocol (JEP) and the Human Judgment Structure (HJS) framework. As a minimalist open standard, JEP generates tamper-proof records of AI decision accountability, just like an aircraft black box; HJS embeds human judgment logic into AI operation processes — together, they transform "human oversight" from a regulatory requirement into a verifiable technical fact, providing an optional technical solution for AI accountability. How to prove that AI decisions (such as loan approvals, medical diagnoses, border screenings, etc.) have undergone human review? JEP generates immutable audit trails of human intervention through four cryptographic primitives — Judge, Verify, Delegate, Terminate; HJS builds a controllable and accountable system to prevent risks such as AI drift and ensure that human judgment guides AI operations. Current systems rely on alterable post-hoc documentation,
Power Integrations Extends Flyback Topology to Enable 440 W, Offering Simpler Alternatives to Resonant Power Designs23.3.2026 22:45:00 CET | Press release
New TOPSwitchGaN ICs more than double power output, reducing system cost, complexity, and design time APEC 2026 – Power Integrations (NASDAQ: POWI), the leader in high-voltage integrated circuits for energy-efficient power conversion, today introduced a breakthrough in flyback topology extending the power range of flyback converters to 440 W—well beyond the limits that traditionally required more complex resonant and LLC topologies. The new TOPSwitchGaN™ flyback IC family unites the company’s groundbreaking PowiGaN™ technology with its iconic TOPSwitch™ IC architecture, reducing complexity, eliminating heat sinks in many cases, shortening design time, improving manufacturability, and lowering total system cost. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260323686299/en/ The new TOPSwitchGaN™ flyback IC family extends the power range of flyback converters to 440 W—well beyond the limits that traditionally required more co
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom